BiotechTV - News cover image

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

BiotechTV - News

00:00

Distinct CBP/p300 Inhibitor Chemistry

Stefanie Fluckiger-Mangual compares Tolremo’s phenotypically discovered CBP/p300 bromodomain inhibitor with CellCentric’s different chemistry.

Play episode from 01:38
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app